FENIX PHARMA È BEST WORKPLACES™ ITALIA 2025
30/03/2025/by Daniele MosettiFENIX PHARMA DEBUTS AS EXHIBITOR AT ARAB HEALTH IN DUBAI
22/01/2025/by Fenix PharmaFenix Pharma promotes the technological transition - Digitalization Voucher for SMEs – Regional FESR Lazio Program 2021-2027
02/10/2024/by Fenix PharmaWAVE PHARMA in support of women with breast cancer in Nepal
05/10/2023/by Fenix PharmaHericium erinaceus, in combination with natural flavonoids/alkaloids and vitamins B3/B8, may improve the inflammatory state in the tissues of inflammatory bowel diseases: an ex vivo study
29/09/2023/by Fenix PharmaFenix Pharma acquires Wave Pharma: new opportunities in oncology.
17/01/2023/by Daniele MosettiFenix Pharma present at the IX edition of the National GCORL Congress.
17/11/2022/by Daniele MosettiEffectiveness of a nutraceutical based on alpha-lipoic acid, acetyl L-carnitine, and B vitamin complex in the treatment of craniofacial neuralgias and tinnitus.
29/09/2022/by Daniele MosettiPerformance of a nutraceutical with a multi-component formulation in patients with symptomatic uncomplicated diverticular disease (SUDD).
30/06/2022/by Fenix PharmaRecent Posts
- FENIX PHARMA È BEST WORKPLACES™ ITALIA 2025
- FENIX PHARMA DEBUTS AS EXHIBITOR AT ARAB HEALTH IN DUBAI
- Fenix Pharma promotes the technological transition - Digitalization Voucher for SMEs – Regional FESR Lazio Program 2021-2027
- WAVE PHARMA in support of women with breast cancer in Nepal
- Hericium erinaceus, in combination with natural flavonoids/alkaloids and vitamins B3/B8, may improve the inflammatory state in the tissues of inflammatory bowel diseases: an ex vivo study
Archives
Where we are
CERTIFICATION
ISO 13485:2021
UNI/PDR 125:2022
Fenix Pharma scpa organization with a gender equality management system certified according to UNI/PdR 125:2022 by the Kiwa Cermet Italia Certification Body, with the UNI Mark
Fenix Pharma s.c.p.a. has received the recognition of Great Place to Work® Certified Company
FENIX PHARMA SOC.COOP.P.A
OPERATIVE HEADQUARTERS:
Via Giunio Antonio Resti, 71
00143 ROMA
Tel: +39 06 59648429
Fax: +39 06 59633037
Where we are
FENIX PHARMA SOC. COOP, as the Data Controller and Data Retention Holder in compliance with the provisions of GDPR 679/2016, has appointed Dr. Antonello Dionisi as Data Protection Officer with full responsibilities as required by the current regulations.
The D.P.O. can be freely contacted at the email: [email protected].
English 
Italian